Since we provide here, only a theoretial context for Nrf2-mediated therapy against DMD, further translational investigations on the therapeutic effects and safety of novel, as well as repurposed, modulators of the Nrf2 signalling pathway should be undertaken in clinical trials. This evidence concerns the gene NFE2L2 and Duchenne muscular dystrophy.